Atossa Genetics (NASDAQ:ATOS) Share Price Crosses Below 200 Day Moving Average – Here’s What Happened

by · The Cerbat Gem

Atossa Genetics Inc. (NASDAQ:ATOS – Get Free Report)’s stock price passed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $5.99 and traded as low as $1.9250. Atossa Genetics shares last traded at $1.93, with a volume of 73,866 shares traded.

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. Ascendiant Capital Markets reduced their price objective on shares of Atossa Genetics from $120.00 to $24.00 and set a “buy” rating for the company in a research note on Friday, April 10th. HC Wainwright increased their target price on shares of Atossa Genetics to $25.00 and gave the company a “buy” rating in a report on Thursday, March 26th. Finally, Weiss Ratings downgraded shares of Atossa Genetics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, June 11th. Two analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. According to MarketBeat, Atossa Genetics has an average rating of “Hold” and a consensus price target of $24.50.

View Our Latest Report on ATOS

Atossa Genetics Stock Performance

The firm has a market capitalization of $18.25 million, a PE ratio of -0.66 and a beta of 1.25. The firm’s 50-day moving average is $4.15 and its 200 day moving average is $5.84.

Atossa Genetics (NASDAQ:ATOS – Get Free Report) last announced its earnings results on Friday, May 8th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.99) by ($0.12). As a group, equities analysts anticipate that Atossa Genetics Inc. will post -4.3 earnings per share for the current year.

Institutional Trading of Atossa Genetics

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. increased its position in Atossa Genetics by 4.2% during the 3rd quarter. Vanguard Group Inc. now owns 6,078,844 shares of the company’s stock worth $5,270,000 after purchasing an additional 245,717 shares in the last quarter. Ameriprise Financial Inc. acquired a new position in Atossa Genetics in the 2nd quarter valued at about $2,468,000. Renaissance Technologies LLC lifted its holdings in Atossa Genetics by 33.2% in the 4th quarter. Renaissance Technologies LLC now owns 2,062,838 shares of the company’s stock valued at $1,217,000 after purchasing an additional 514,175 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Atossa Genetics by 0.7% during the 4th quarter. Geode Capital Management LLC now owns 1,371,909 shares of the company’s stock worth $810,000 after purchasing an additional 9,627 shares during the last quarter. Finally, State Street Corp boosted its stake in shares of Atossa Genetics by 31.2% during the 4th quarter. State Street Corp now owns 596,485 shares of the company’s stock worth $352,000 after purchasing an additional 141,990 shares during the last quarter. 12.74% of the stock is currently owned by hedge funds and other institutional investors.

About Atossa Genetics

(Get Free Report)

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.

Featured Articles